Published in Cancer Metab on July 17, 2014
Pyruvate carboxylation enables growth of SDH-deficient cells by supporting aspartate biosynthesis. Nat Cell Biol (2015) 1.22
Mitochondrial division is requisite to RAS-induced transformation and targeted by oncogenic MAPK pathway inhibitors. Mol Cell (2015) 1.17
Mitochondria and Cancer. Mol Cell (2016) 1.11
Metabostemness: a new cancer hallmark. Front Oncol (2014) 1.05
Measuring In Vivo Mitophagy. Mol Cell (2015) 0.96
Autophagy, Metabolism, and Cancer. Clin Cancer Res (2015) 0.95
Loss of succinate dehydrogenase activity results in dependency on pyruvate carboxylation for cellular anabolism. Nat Commun (2015) 0.92
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis. Oncotarget (2016) 0.89
Identification of potential mitochondrial CLPXP protease interactors and substrates suggests its central role in energy metabolism. Sci Rep (2015) 0.88
Pituitary adenoma with paraganglioma/pheochromocytoma (3PAs) and succinate dehydrogenase defects in humans and mice. J Clin Endocrinol Metab (2015) 0.85
Succinate dehydrogenase subunit B inhibits the AMPK-HIF-1α pathway in human ovarian cancer in vitro. J Ovarian Res (2014) 0.82
Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. Oncotarget (2015) 0.81
Oxidative phosphorylation-dependent regulation of cancer cell apoptosis in response to anticancer agents. Cell Death Dis (2015) 0.81
Citrate synthase expression affects tumor phenotype and drug resistance in human ovarian carcinoma. PLoS One (2014) 0.80
Molecular magnetic resonance imaging in cancer. J Transl Med (2015) 0.79
The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy. BMC Cancer (2015) 0.79
Reconstruction of Tissue-Specific Metabolic Networks Using CORDA. PLoS Comput Biol (2016) 0.79
Tumor Metabolism, the Ketogenic Diet and β-Hydroxybutyrate: Novel Approaches to Adjuvant Brain Tumor Therapy. Front Mol Neurosci (2016) 0.79
Foxg1 localizes to mitochondria and coordinates cell differentiation and bioenergetics. Proc Natl Acad Sci U S A (2015) 0.78
The Dual Function of Reactive Oxygen/Nitrogen Species in Bioenergetics and Cell Death: The Role of ATP Synthase. Oxid Med Cell Longev (2016) 0.78
SIRT3 as a Regulator of Non-alcoholic Fatty Liver Disease. J Lifestyle Med (2014) 0.78
Heme oxygenase-1 in macrophages controls prostate cancer progression. Oncotarget (2015) 0.77
Mitochondrial metabolic remodeling in response to genetic and environmental perturbations. Wiley Interdiscip Rev Syst Biol Med (2016) 0.76
Changing perspective on oncometabolites: from metabolic signature of cancer to tumorigenic and immunosuppressive agents. Oncotarget (2016) 0.76
A Novel Malate Dehydrogenase 2 Inhibitor Suppresses Hypoxia-Inducible Factor-1 by Regulating Mitochondrial Respiration. PLoS One (2016) 0.76
Mitochondrial dysfunction in cancer: Potential roles of ATF5 and the mitochondrial UPR. Semin Cancer Biol (2017) 0.75
The Chaperone TRAP1 As a Modulator of the Mitochondrial Adaptations in Cancer Cells. Front Oncol (2017) 0.75
Targeting the Metabolic Reprogramming That Controls Epithelial-to-Mesenchymal Transition in Aggressive Tumors. Front Oncol (2017) 0.75
Paving the way for therapeutic prevention of tumor metastasis with agents targeting mitochondrial superoxide. Mol Cell Oncol (2014) 0.75
Recursive Random Lasso (RRLasso) for Identifying Anti-Cancer Drug Targets. PLoS One (2015) 0.75
The Close Interconnection between Mitochondrial Dynamics and Mitophagy in Cancer. Front Oncol (2017) 0.75
The opposite prognostic effect of NDUFS1 and NDUFS8 in lung cancer reflects the oncojanus role of mitochondrial complex I. Sci Rep (2016) 0.75
Mitochondrially targeted fluorescent redox sensors. Interface Focus (2017) 0.75
Oncogenic regulation of tumor metabolic reprogramming. Oncotarget (2016) 0.75
Sending Out an SOS: Mitochondria as a Signaling Hub. Front Cell Dev Biol (2016) 0.75
A combination of high dose rate (10X FFF/2400 MU/min/10 MV X-rays) and total low dose (0.5 Gy) induces a higher rate of apoptosis in melanoma cells in vitro and superior preservation of normal melanocytes. Melanoma Res (2015) 0.75
Cancer: Untethering Mitochondria from the Endoplasmic Reticulum? Front Oncol (2017) 0.75
Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition. Oncogene (2017) 0.75
The consensus coding sequences of human breast and colorectal cancers. Science (2006) 60.02
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
On the origin of cancer cells. Science (1956) 49.55
Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09
IDH1 and IDH2 mutations in gliomas. N Engl J Med (2009) 32.41
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell (2010) 15.20
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell (2010) 13.13
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44
Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell (2005) 9.33
Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science (2000) 8.64
Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet (2002) 8.19
Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A (2010) 8.12
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature (2012) 7.95
HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell (2007) 6.31
Cooperation and competition in the evolution of ATP-producing pathways. Science (2001) 6.04
ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science (2008) 5.54
Endosymbiotic gene transfer: organelle genomes forge eukaryotic chromosomes. Nat Rev Genet (2004) 5.51
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stability. Cancer Cell (2005) 5.47
The hydrogen hypothesis for the first eukaryote. Nature (1998) 5.26
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A (2011) 5.24
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep (2011) 4.89
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science (2013) 4.88
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (2000) 4.87
Mitochondria and cancer. Nat Rev Cancer (2012) 4.81
Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet (1998) 4.67
mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A (2005) 4.66
Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers. Int J Cancer (2009) 4.45
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. Nature (2012) 4.37
Mitochondrial DNA mutations in human cancer. Oncogene (2006) 4.08
Mitochondria as sensors and regulators of calcium signalling. Nat Rev Mol Cell Biol (2012) 3.59
SDH mutations establish a hypermethylator phenotype in paraganglioma. Cancer Cell (2013) 3.24
Renal cyst formation in Fh1-deficient mice is independent of the Hif/Phd pathway: roles for fumarate in KEAP1 succination and Nrf2 signaling. Cancer Cell (2011) 3.00
Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci U S A (2013) 2.96
Germline SDHB mutations and familial renal cell carcinoma. J Natl Cancer Inst (2008) 2.89
The pathways of glutamate and glutamine oxidation by tumor cell mitochondria. Role of mitochondrial NAD(P)+-dependent malic enzyme. J Biol Chem (1984) 2.82
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell (2011) 2.78
Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev (2012) 2.70
Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations. Proc Natl Acad Sci U S A (2010) 2.68
Why do we still have a maternally inherited mitochondrial DNA? Insights from evolutionary medicine. Annu Rev Biochem (2007) 2.39
Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence. Nature (2013) 2.29
Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides. Nature (2014) 2.27
Succinate dehydrogenase mutation underlies global epigenomic divergence in gastrointestinal stromal tumor. Cancer Discov (2013) 2.11
Energetics, epigenetics, mitochondrial genetics. Mitochondrion (2009) 2.08
Mitochondrial diseases. Lancet (2012) 2.08
Mitochondrial permeability transition in Ca(2+)-dependent apoptosis and necrosis. Cell Calcium (2011) 2.06
Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis (2002) 2.04
Origin and evolution of eukaryotic apoptosis: the bacterial connection. Cell Death Differ (2002) 2.04
Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res (2001) 1.96
Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by prevention from apoptosis. Cancer Res (2005) 1.90
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
The production of reactive oxygen species by complex I. Biochem Soc Trans (2008) 1.87
High incidence of somatic mitochondrial DNA mutations in human ovarian carcinomas. Cancer Res (2001) 1.80
Inhibition of succinate dehydrogenase dysregulates histone modification in mammalian cells. Mol Cancer (2009) 1.62
Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hürthle cell tumors. Am J Pathol (2002) 1.61
Mitochondrial aconitase and citrate metabolism in malignant and nonmalignant human prostate tissues. Mol Cancer (2006) 1.57
The proto-oncometabolite fumarate binds glutathione to amplify ROS-dependent signaling. Mol Cell (2013) 1.54
Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. Cancer Res (2008) 1.41
The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab (2013) 1.36
Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma. Clin Cancer Res (2014) 1.33
Symbiotic theory of the origin of eukaryotic organelles; criteria for proof. Symp Soc Exp Biol (1975) 1.25
Diminished tumorigenic phenotype after depletion of mitochondrial DNA. Cell Growth Differ (1997) 1.19
Germline mutations in FH confer predisposition to malignant pheochromocytomas and paragangliomas. Hum Mol Genet (2013) 1.14
Citrate as an in vivo marker to discriminate prostate cancer from benign prostatic hyperplasia and normal prostate peripheral zone: detection via localized proton spectroscopy. Urology (1995) 1.12
Sodium, potassium, calcium, magnesium, zinc, citrate and chloride content of human prostatic and seminal fluid. J Reprod Fertil (1985) 1.11
Inherited variants in mitochondrial biogenesis genes may influence epithelial ovarian cancer risk. Cancer Epidemiol Biomarkers Prev (2011) 1.11
Involvement of cytochrome c oxidase subunits Va and Vb in the regulation of cancer cell metabolism by Bcl-2. Cell Death Differ (2009) 1.09
Inhibition of mitochondrial aconitase by succination in fumarate hydratase deficiency. Cell Rep (2013) 1.08
Impaired OXPHOS complex III in breast cancer. PLoS One (2011) 1.07
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci (2007) 1.01
Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med (2013) 1.00
Reversed argininosuccinate lyase activity in fumarate hydratase-deficient cancer cells. Cancer Metab (2013) 1.00
Inhibition of ATPIF1 ameliorates severe mitochondrial respiratory chain dysfunction in mammalian cells. Cell Rep (2014) 0.98
Reduced expression of fumarate hydratase in clear cell renal cancer mediates HIF-2α accumulation and promotes migration and invasion. PLoS One (2011) 0.97
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. Cancer Metab (2013) 0.96
Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancy. Sci Rep (2012) 0.96
Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2. PLoS One (2010) 0.95
Non-enzymatic chemistry enables 2-hydroxyglutarate-mediated activation of 2-oxoglutarate oxygenases. Nat Commun (2014) 0.93
Active oxidative decarboxylation of malate by mitochondria isolated from L-1210 ascites tumor cells. Biochem Biophys Res Commun (1973) 0.93
Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas. Int J Cancer (2011) 0.92
Forced cytochrome B gene mutation expression induces mitochondrial proliferation and prevents apoptosis in human uroepithelial SV-HUC-1 cells. Int J Cancer (2009) 0.91
Suppression of mitochondrial complex I influences cell metastatic properties. PLoS One (2013) 0.90
Enhanced citrate synthase activity in human pancreatic cancer. Pancreas (2005) 0.89
Succinate dehydrogenase expression in breast cancer. Springerplus (2013) 0.86
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment. Hum Mol Genet (2013) 0.85
Nuclear ARRB1 induces pseudohypoxia and cellular metabolism reprogramming in prostate cancer. EMBO J (2014) 0.85
Hypoxia upregulates the gene expression of mitochondrial aconitase in prostate carcinoma cells. J Mol Endocrinol (2013) 0.84
The role of mitochondria in the oncogenic signal transduction. Int J Biochem Cell Biol (2014) 0.84
Decreased expression of the mitochondrial metabolic enzyme aconitase (ACO2) is associated with poor prognosis in gastric cancer. Med Oncol (2013) 0.84
Succinate: a new epigenetic hacker. Cancer Cell (2013) 0.83
Cytochrome c oxidase is activated by the oncoprotein Ras and is required for A549 lung adenocarcinoma growth. Mol Cancer (2012) 0.81
High efficiency versus maximal performance--the cause of oxidative stress in eukaryotes: a hypothesis. Mitochondrion (2012) 0.80